Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.
Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.
复制标题
DOI:
10.1371/journal.ppat.1005016
复制
发表时间:
2015-06
期刊:
影响因子:
6.7
通讯作者:
Saphire EO
中科院分区:
文献类型:
--
作者:
Fusco ML;Hashiguchi T;Cassan R;Biggins JE;Murin CD;Warfield KL;Li S;Holtsberg FW;Shulenin S;Vu H;Olinger GG;Kim DH;Whaley KJ;Zeitlin L;Ward AB;Nykiforuk C;Aman MJ;Berry JD;Saphire EO
The filoviruses, which include the marburg- and ebolaviruses, have caused multiple outbreaks among humans this decade. Antibodies against the filovirus surface glycoprotein (GP) have been shown to provide life-saving therapy in nonhuman primates, but such antibodies are generally virus-specific. Many monoclonal antibodies (mAbs) have been described against Ebola virus. In contrast, relatively few have been described against Marburg virus. Here we present ten mAbs elicited by immunization of mice using recombinant mucin-deleted GPs from different Marburg virus (MARV) strains. Surprisingly, two of the mAbs raised against MARV GP also cross-react with the mucin-deleted GP cores of all tested ebolaviruses (Ebola, Sudan, Bundibugyo, Reston), but these epitopes are masked differently by the mucin-like domains themselves. The most efficacious mAbs in this panel were found to recognize a novel “wing” feature on the GP2 subunit that is unique to Marburg and does not exist in Ebola. Two of these anti-wing antibodies confer 90 and 100% protection, respectively, one hour post-exposure in mice challenged with MARV. The filoviruses have caused multiple outbreaks among humans this decade, including a 90% lethal outbreak of Marburg virus in Angola and a significant, sustained outbreak of Ebola virus in West Africa. The viral surface glycoprotein (GP), which enables filoviruses to infect host cells, is the primary target of the immune system. Antibodies that target filovirus GP have been shown to provide life-saving therapy in nonhuman primates. However, the majority of known antibodies are only reactive against Ebola virus and not other emerging filoviruses. In this study, we present ten antibodies against Marburg virus, elicited by immunization of mice using engineered forms of its GP. Surprisingly, two antibodies exhibit some cross-reactivity to ebolaviruses (including species Ebola, Sudan, Bundibugyo, Reston). Other antibodies in this panel recognize a novel “wing” feature on a portion of GP that is unique to Marburg and does not exist in ebolaviruses, and protect 90%-100% of mice from lethal exposure. These antibodies, and their structural and functional analysis presented here, illuminate directions forward for therapeutics against Marburg virus.
登录
查看更多内容
影响因子:
64.8
作者:
Cote, Marceline;Misasi, John;Ren, Tao;Bruchez, Anna;Lee, Kyungae;Filone, Claire Marie;Hensley, Lisa;Li, Qi;Ory, Daniel;Chandran, Kartik;Cunningham, James
通讯作者:
Cunningham, James
影响因子:
5.4
作者:
Hood, Chantelle L.;Abraham, Jonathan;Nabel, Gary J.
通讯作者:
Nabel, Gary J.
影响因子:
56.9
作者:
KISSLING, RE;ROBINSON, RQ;WHITFIELD, SG
通讯作者:
WHITFIELD, SG
影响因子:
2.7
作者:
Kuhn, Jens H.;Becker, Stephan;Ebihara, Hideki;Geisbert, Thomas W.;Johnson, Karl M.;Kawaoka, Yoshihiro;Lipkin, W. Ian;Negredo, Ana I.;Netesov, Sergey V.;Nichol, Stuart T.;Palacios, Gustavo;Peters, Clarence J.;Tenorio, Antonio;Volchkov, Viktor E.;Jahrling, Peter B.
通讯作者:
Jahrling, Peter B.
影响因子:
3.7
作者:
Marzi A;Yoshida R;Miyamoto H;Ishijima M;Suzuki Y;Higuchi M;Matsuyama Y;Igarashi M;Nakayama E;Kuroda M;Saijo M;Feldmann F;Brining D;Feldmann H;Takada A
通讯作者:
Takada A